Literature DB >> 19454452

Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

S Aebi1, M Castiglione.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19454452     DOI： 10.1093/annonc/mdp117

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  13 in total

1.  Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.

Authors:  Teresa Granato; Cecilia Midulla; Flavia Longo; Barbara Colaprisca; Luigi Frati; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2012-04-13

Review 2.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

3.  Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Authors:  Elisabetta Bandiera; Chiara Romani; Claudia Specchia; Laura Zanotti; Claudio Galli; Giuseppina Ruggeri; Germana Tognon; Eliana Bignotti; Renata A Tassi; Franco Odicino; Luigi Caimi; Enrico Sartori; Alessandro D Santin; Sergio Pecorelli; Antonella Ravaggi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

Review 4.  Splenectomy for non-haematological metastatic malignant disease.

Authors:  Piers A C Gatenby; Satvinder S Mudan; Andrew C Wotherspoon
Journal:  Langenbecks Arch Surg       Date:  2011-02-17       Impact factor: 3.445

5.  Low 25-OH vitamin D levels at time of diagnosis and recurrence of ovarian cancer.

Authors:  Teresa Granato; Lucia Manganaro; Luca Petri; Maria Grazia Porpora; Valentina Viggiani; Antonio Angeloni; Emanuela Anastasi
Journal:  Tumour Biol       Date:  2015-09-09

Review 6.  New ways of assessing ovarian cancer response: metabolic imaging and beyond.

Authors:  Andrea Rockall; Alice Munari; Norbert Avril
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

7.  Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.

Authors:  Katarzyna M Terlikowska; Bozena Dobrzycka; Anna M Witkowska; Beata Mackowiak-Matejczyk; Tomasz Kamil Sledziewski; Maciej Kinalski; Slawomir J Terlikowski
Journal:  J Ovarian Res       Date:  2016-07-19       Impact factor: 4.234

8.  Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Authors:  Elham O Hamed; Hydi Ahmed; Osama B Sedeek; Abeer M Mohammed; Ali A Abd-Alla; Hazem M Abdel Ghaffar
Journal:  Diagn Pathol       Date:  2013-01-23       Impact factor: 2.644

9.  Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.

Authors:  Lubomir Bodnar; Aleksandra Stanczak; Szczepan Cierniak; Marta Smoter; Marzena Cichowicz; Wojciech Kozlowski; Cezary Szczylik; Maciej Wieczorek; Monika Lamparska-Przybysz
Journal:  J Ovarian Res       Date:  2014-02-06       Impact factor: 4.234

10.  Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.

Authors:  J Sehouli; A Reinthaller; C Marth; D Reimer; T Reimer; W Stummvoll; L Angleitner-Boubenizek; B Brandt; R Chekerov
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.